vs

Side-by-side financial comparison of GCM Grosvenor Inc. (GCMG) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $177.1M, roughly 1.8× GCM Grosvenor Inc.). GCM Grosvenor Inc. runs the higher net margin — 32.8% vs -18.2%, a 51.1% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 7.2%). GCM Grosvenor Inc. produced more free cash flow last quarter ($175.0M vs $-133.8M).

GCM Grosvenor is an American alternative asset management firm, with approximately $76 billion in assets under management and approximately 530 professionals as of 2023.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

GCMG vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.8× larger
MDGL
$321.1M
$177.1M
GCMG
Growing faster (revenue YoY)
MDGL
MDGL
+203.6% gap
MDGL
210.8%
7.2%
GCMG
Higher net margin
GCMG
GCMG
51.1% more per $
GCMG
32.8%
-18.2%
MDGL
More free cash flow
GCMG
GCMG
$308.9M more FCF
GCMG
$175.0M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GCMG
GCMG
MDGL
MDGL
Revenue
$177.1M
$321.1M
Net Profit
$58.2M
$-58.6M
Gross Margin
Operating Margin
30.9%
-18.6%
Net Margin
32.8%
-18.2%
Revenue YoY
7.2%
210.8%
Net Profit YoY
149.2%
1.4%
EPS (diluted)
$0.23
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GCMG
GCMG
MDGL
MDGL
Q4 25
$177.1M
$321.1M
Q3 25
$135.0M
$287.3M
Q2 25
$119.7M
$212.8M
Q1 25
$125.8M
$137.3M
Q4 24
$165.3M
$103.3M
Q3 24
$122.9M
$62.2M
Q2 24
$117.0M
Q1 24
$108.9M
$0
Net Profit
GCMG
GCMG
MDGL
MDGL
Q4 25
$58.2M
$-58.6M
Q3 25
$10.5M
$-114.2M
Q2 25
$15.4M
$-42.3M
Q1 25
$463.0K
$-73.2M
Q4 24
$7.6M
$-59.4M
Q3 24
$4.2M
$-107.0M
Q2 24
$4.8M
Q1 24
$2.1M
$-147.5M
Gross Margin
GCMG
GCMG
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
GCMG
GCMG
MDGL
MDGL
Q4 25
30.9%
-18.6%
Q3 25
32.7%
-39.7%
Q2 25
16.1%
-22.2%
Q1 25
12.2%
-57.8%
Q4 24
26.4%
-64.8%
Q3 24
20.3%
-187.1%
Q2 24
17.8%
Q1 24
-14.7%
Net Margin
GCMG
GCMG
MDGL
MDGL
Q4 25
32.8%
-18.2%
Q3 25
7.8%
-39.8%
Q2 25
12.9%
-19.9%
Q1 25
0.4%
-53.4%
Q4 24
4.6%
-57.5%
Q3 24
3.4%
-172.0%
Q2 24
4.1%
Q1 24
2.0%
EPS (diluted)
GCMG
GCMG
MDGL
MDGL
Q4 25
$0.23
$-2.55
Q3 25
$0.16
$-5.08
Q2 25
$0.05
$-1.90
Q1 25
$-0.02
$-3.32
Q4 24
$0.09
$-2.50
Q3 24
$0.03
$-4.92
Q2 24
$0.04
Q1 24
$-0.13
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GCMG
GCMG
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$242.1M
$198.7M
Total DebtLower is stronger
$428.4M
$339.9M
Stockholders' EquityBook value
$27.0M
$602.7M
Total Assets
$813.8M
$1.3B
Debt / EquityLower = less leverage
15.87×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GCMG
GCMG
MDGL
MDGL
Q4 25
$242.1M
$198.7M
Q3 25
$182.7M
$295.7M
Q2 25
$136.3M
$186.2M
Q1 25
$94.5M
$183.6M
Q4 24
$89.5M
$100.0M
Q3 24
$98.4M
$232.7M
Q2 24
$73.9M
Q1 24
$41.9M
$622.5M
Total Debt
GCMG
GCMG
MDGL
MDGL
Q4 25
$428.4M
$339.9M
Q3 25
$429.3M
$339.8M
Q2 25
$430.2M
$118.4M
Q1 25
$431.1M
$118.0M
Q4 24
$432.0M
$117.6M
Q3 24
$432.9M
$117.1M
Q2 24
$433.8M
Q1 24
$384.0M
$116.1M
Stockholders' Equity
GCMG
GCMG
MDGL
MDGL
Q4 25
$27.0M
$602.7M
Q3 25
$-7.4M
$625.7M
Q2 25
$-12.3M
$696.0M
Q1 25
$-28.3M
$710.6M
Q4 24
$-27.6M
$754.4M
Q3 24
$-31.9M
$777.2M
Q2 24
$-28.5M
Q1 24
$-26.4M
$850.8M
Total Assets
GCMG
GCMG
MDGL
MDGL
Q4 25
$813.8M
$1.3B
Q3 25
$685.9M
$1.4B
Q2 25
$636.9M
$1.0B
Q1 25
$579.8M
$996.6M
Q4 24
$612.7M
$1.0B
Q3 24
$575.0M
$1.1B
Q2 24
$543.9M
Q1 24
$497.3M
$1.1B
Debt / Equity
GCMG
GCMG
MDGL
MDGL
Q4 25
15.87×
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GCMG
GCMG
MDGL
MDGL
Operating Cash FlowLast quarter
$183.5M
$-133.5M
Free Cash FlowOCF − Capex
$175.0M
$-133.8M
FCF MarginFCF / Revenue
98.8%
-41.7%
Capex IntensityCapex / Revenue
4.8%
0.1%
Cash ConversionOCF / Net Profit
3.16×
TTM Free Cash FlowTrailing 4 quarters
$326.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GCMG
GCMG
MDGL
MDGL
Q4 25
$183.5M
$-133.5M
Q3 25
$79.8M
$79.8M
Q2 25
$42.0M
$-47.1M
Q1 25
$33.3M
$-88.9M
Q4 24
$148.8M
$-104.5M
Q3 24
$69.0M
$-67.0M
Q2 24
$17.5M
Q1 24
$24.2M
$-149.2M
Free Cash Flow
GCMG
GCMG
MDGL
MDGL
Q4 25
$175.0M
$-133.8M
Q3 25
$78.3M
$79.0M
Q2 25
$40.8M
Q1 25
$32.1M
Q4 24
$132.0M
$-104.7M
Q3 24
$62.2M
$-67.8M
Q2 24
$12.8M
Q1 24
$20.0M
$-149.5M
FCF Margin
GCMG
GCMG
MDGL
MDGL
Q4 25
98.8%
-41.7%
Q3 25
58.0%
27.5%
Q2 25
34.1%
Q1 25
25.5%
Q4 24
79.9%
-101.3%
Q3 24
50.6%
-109.0%
Q2 24
10.9%
Q1 24
18.4%
Capex Intensity
GCMG
GCMG
MDGL
MDGL
Q4 25
4.8%
0.1%
Q3 25
1.1%
0.3%
Q2 25
1.0%
0.0%
Q1 25
0.9%
0.0%
Q4 24
10.1%
0.2%
Q3 24
5.5%
1.3%
Q2 24
4.0%
Q1 24
3.9%
Cash Conversion
GCMG
GCMG
MDGL
MDGL
Q4 25
3.16×
Q3 25
7.61×
Q2 25
2.72×
Q1 25
71.84×
Q4 24
19.54×
Q3 24
16.60×
Q2 24
3.64×
Q1 24
11.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GCMG
GCMG

Asset Management1$108.6M61%
Management Service Incentive Performance Fees$61.7M35%
Management Service Incentive Carried Interest$5.1M3%
Service Other$1.8M1%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons